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ABSTRACT 
Objective: To evaluate the prevalence of prior inflammatory events in patients consulting for 
a first inflammatory neurological event, and improve early diagnosis of multiple sclerosis. 
Methods: During the initial visit, the neurologist gave patients a self-administered 
questionnaire containing 72 questions regarding previous symptoms lasting more than 24 
hours. During the follow-up visit the neurologist validated the symptoms and collected 
information about the current attack.  
Results: The cohort included 178 patients (74% women, mean age (±SD) 33.7 (±10.1) years). 
The main reason for the initial visit was visual disturbance and sensory troubles in limbs. 
Mean (±SD) global EDSS score was 1.4 (±1.1), 46% of brains MRIs were positive according 
to Barkhof-Tintoré criteria, 41% had abnormal WBC count in CSF and 71% had IgG 
oligoclonal bands. Prior symptoms suggestive of demyelination were reported by 79 patients 
(44%), validated by the neurologist for 70% (55 patients) and identified only by the 
neurologist in four patients. Sequelae were observed in 14 patients with validated prior 
symptoms (26%). The self-administered questionnaire showed an overall sensitivity of 93% 
and specificity of 80% for identifying patients with prior symptoms suggestive of 
demyelination.  
Conclusion: A patient-administered questionnaire subsequently validated by the neurologist 
demonstrated that 33% of patients consulting for a first demyelinating event had prior 
symptoms suggestive of CNS demyelination that had gone unnoticed, and almost 70% had 
either sequelae of prior demyelination or McDonald criteria for dissemination in space. Such 
a questionnaire could be a useful tool for earlier diagnosis of multiple sclerosis. 
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INTRODUCTION 
In multiple sclerosis (MS) the notion of first attack is still vague. Before the clinical event that 
leads to consultation in a hospital’s Neurology department, there are often preexisting 
symptoms suggestive of MS such as fatigue, limb weakness, blurred vision, paresthesias, 
vertigo, and urinary disturbances[1]. These initial symptoms correspond to the Clinically 
Isolated Syndrome (CIS). In the study Optic Neuritis Treatment Trial (ONTT) [2, 3] 
antecedents such as those described above (mostly paresthesia) were identified in 45 of 149 
(30%) patients who had abnormal cerebral Magnetic Resonance Imaging (MRI) and 12 of 
202 (5.9%) patients with normal MRI. For all patients, whatever the MRI result, presence of 
such an antecedent was a risk factor for developing clinically definite MS within 5 years. 
Furthermore, according to McDonald’s new criteria for MS diagnosis, [4, 5] patients who 
presented at the first attack with sequelae of a preexisting symptom suggestive of a 
demyelinating event (i.e., lasting at least for 24 hours), can be considered as having MS, as 
can patients who have had 2 attacks in addition to clinical evidence of one lesion and criteria 
for dissemination in space, which is demonstrated by MRI or at least 2T2 lesions and a 
positive cerebrospinal fluid (CSF). Therefore, the primary objective of the present study was 
to evaluate the prevalence of patients presenting with antecedents suggestive of 
demyelinating event(s) that went unnoticed among patients consulting or hospitalised in a 
Neurology department for a first inflammatory demyelinating event and to initiate the 
development of a specific screening questionnaire to accurately identify these suggestive 
antecedents.  
 
METHODS 
Patients 
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Patients included in the study were male and female adults who had been hospitalised or seen 
in the Neurology outpatient clinics for a first inflammatory neurological event.  
Study design 
This was a prospective, multicenter, observational pilot study, conducted in 14 French 
reference hospital neurology departments specialising in MS. The objective was to collect 
data on neurological antecedents in patients hospitalised for a first demyelinating event (i.e., 
CIS) as well as data on environmental factors and family history that could affect the 
management and evolution of the disease. Patients were included in the study after being 
informed about the study by the neurologist. At the initial visit, the neurologist gave a self-
administered questionnaire to patients about antecedents suggestive of a first demyelinating 
event. Patients were invited to fill out the questionnaire at home and to return it at the next 
planned visit. Questions were about demographic data (age, sex, marital status), socio-
geographic characteristics (occupation, educational level, residence area), and neurologically 
relevant medical and family history. In particular, the patient had to describe all previous 
symptoms lasting more than 24 hours that could be related to a CNS demyelination: fatigue, 
visual disturbance (diplopia, blurred vision, and ocular pain), sensations (tingling, burning, 
numbness, electrical shock in one or several limbs), clumsiness (hand clumsiness, impaired 
walking, and limb muscle weakness), bladder problems (urinary urgency or retention), loss of 
balance, vertigo, hearing disturbance, and facial paralysis. During the normal follow-up visit 
(usually one to two months after the initial visit), the patient returned the completed 
questionnaire to the neurologist, who then reviewed it with the patient. The neurologist then 
completed part of the questionnaire, indicating: onset of the current attack, supposed 
localisation of the neurological lesion, Expanded Disability Status Scale (EDSS) score, [6] 
and signs and symptoms attesting to the antecedents reported by the patient. The neurologist 
also reported all available results of complementary tests concerning this current attack, 
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including brain MRI, Barkhof-Tintoré criteria[7, 8] evaluation, and lumbar puncture. All 
brain MRI was performed on 1.5-Tesla scanner and IgG oligoclonal bands were detected by 
isoelectric focusing. 
Statistical methods 
Descriptive statistics were performed for all patients or events, and for selected sub-groups. 
For quantitative variables, the total number, mean, standard deviation (SD), median, quartiles, 
and range were calculated. For qualitative data, the total number, percentages, and 95% 
Confidence Interval were calculated. Comparisons between groups (Chi2, Fisher and 
Wilcoxon tests) and correlations were performed considering α risk at level 5%. An analysis 
of sensitivity and specificity was performed on the questionnaire. 
 
RESULTS 
Population description 
A total of 178 patients were included: 131 women (74%) and 47 men (26%). Mean (±SD) age 
at baseline was 33.7 (±10.1) years, with a range of 15-60 years. A family history of MS was 
reported by 11% of the patients. Most patients (72%) were referred by a specialist, usually an 
ophthalmologist, neurologist, or emergency department physician. The median time between 
the first episode and the patient’s initial visit was 29 days (range, 0-686 days). According to 
the neurologist, the affected area of the CNS was the optical nerve (in 33% of cases), spinal 
cord (37.5%), brainstem (12.5%), or brain (11%). Six percent of patients presented with two 
different affected sites. Mean EDSS score was 1.4 (±1.1).  
Brain MRI results 
MRI was performed for 99% of the patients, and with gadolinium infusion for 94% of 
patients. The mean delay from onset was 27 (± 24) days (range, 0-87 days). MRI was 
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abnormal in 87% of cases and 46% were positive according to Barkhof-Tintoré criteria 
(presenting with at least 3 of the 4 criteria).  
Lumbar puncture – Cerebrospinal fluid (CSF) test 
Lumbar puncture was performed for 87.5% of the patients. The mean white blood cell (WBC) 
count was 7 cells/mm3 (range 0-100). Immunoglobin G (IgG) oligoclonal bands were present 
in 71% of patients.  
Prior symptoms suggestive of demyelination 
A total of 139 prior symptoms suggestive of demyelination were reported by 79 patients 
(44%), and at least one of these suggestive symptoms was validated by the neurologist for 55 
patients (70%) (fig 1). In addition, neurologists identified 12 prior symptoms in 10 patients 
that had not been reported by the patients. Therefore, neurologists identified 59 patients 
(33%) with at least one prior symptom suggestive of demyelination: 36 patients presented 
with a single event and 23 patients presented with several events, usually two or three. The 
mean time period between the first suggestive symptom and the first demyelinating event 
leading to a Neurology department consult was 46 months (range, 1 to 202 months). The most 
frequent events were tingling sensations (9.6% of all patients), visual disturbances (6.2%) and 
muscular weakness in one or several limbs (6.2%). Partial numbness, impaired walking, and 
loss of balance were each suggestive of prior CNS demyelination for 9 patients (5.1%). Six to 
eight patients presented with electrical shock sensation (Lhermitte’s sign), diplopia, fatigue, 
or urinary urgency. Most demyelinating events led to consultation with a general practitioner 
(GP) or a specialist (or both, for 26 patients) but no further investigation had been performed 
to diagnose CNS demyelination. In summary, in terms of identifying patients with at least one 
prior symptom suggestive of demyelination, the self-administered questionnaire had an 
overall sensitivity of 93% and specificity of 80% (table 1). Sensitivity was then analyzed for 
each symptom reported by the patient or identified by the neurologist. Sensitivity was 
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excellent but the rate of false positives was high for vertigo (77%), hearing disturbance 
(75%), bladder problems (63%), and fatigue (58%). Conversely, positive predictive value was 
good (over 70%) for facial paralysis, sensation, and visual disturbance. Comparison of MRI 
findings with the presence or absence of prior symptoms suggestive of demyelination showed 
that abnormal MRI was more frequent in patients with prior symptoms (95% compared to 
84%, p=0.039).  
Sequelae attesting to prior demyelinating events were reported for 14 patients (8% of all 
patients and 26% of patients reporting validated prior symptoms). Finally, according to 
McDonald criteria, 70% of patients with prior symptoms had MS (fig 1). 
 
DISCUSSION 
New MS diagnosis criteria based on MRI findings[9] have good sensitivity and 
specificity.[10-13] In this pilot study, paraclinical results were taken into account to 
standardise diagnosis of a first event of inflammatory demyelination. In addition, a self-
administered questionnaire was tested to identify previous neurological inflammatory events 
suggestive of MS and possible sequelae present at examination in order to fulfil criteria for 
MS. Characteristics of the cohort of patients included in this study were consistent with those 
previously described for patients with inflammatory demyelinating disease. 
Neurologists could identify previous relevant events suggestive of CNS demyelination in 
33% of patients coming to the neurology department for a perceived initial inflammatory 
demyelinating event. Half of these patients had even reported several suggestive prior 
symptoms. There was an average interval of 46 months between these antecedents and the 
current episode leading to neurology department consult. Interesting findings were that most 
of these previous events led patients to visit a GP, a specialist, or both, but did not lead to 
further investigation and special follow-up. The self-administered questionnaire was revealed 
Gout, O - page 10/14  
 
to be a useful tool with which to identify patients with prior symptoms suggestive of 
demyelination. Reported prior symptoms were validated by a neurologist for 70% of patients. 
Neurologists identified only four more patients with suggestive prior symptoms that were not 
reported in the self-administered questionnaire. Finally, symptoms or signs at examination 
attesting to these prior demyelinating events were reported for 24% of patients and criteria for 
dissemination in space were fulfilled in another 46%, leading to a diagnosis of MS in 70% of 
these patients. 
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Figure 1 Flow chart 
 
  
139 prior events reported by 79 Patients 
58 prior 
events not 
validated 
 6 prior events in 4 new patients 
59 patients had prior events validated 
or identified by a neurologist 
45 patients  
(27 had either MRI 
dissemination in space 
or 2T2 lesion and 
IgGOB)  
 
27 had MS and 28 had 
possible MS 
14 patients had 
sequelae of prior 
events (MS patients) 
119 patients had CIS 
(68 had either MRI 
dissemination in space 
or 2T2 lesion and 
IgGOB)  
 
68 had possible MS 
and 51 had CIS 
12 prior events, not reported by 
patients, were identified by 
neurologists in 10 patients 
81 neurologist-validated 
prior events in 55 
patients 
178 patients with a «first demyelinating event» completed the self-administered 
questionnaire 
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Table 1 Sensitivity and specificity of the self-administered questionnaire (Analysis in terms of patients) 
 Reported by the neurologist  
 
Reported by the patient 
At least one relevant prior symptom No relevant prior symptom Total 
At least one prior symptom 55 24 79 
No prior symptom 4 95 99 
    
Total 59 119 178 
   
Positive predictive value (PPV) 69.6% [59.5%; 79.8%] 
Negative predictive value (NPV) 96.0% [92.1%; 99.8%] 
Sensitivity 93.2% [86.8%; 99.6%] 
Specificity 79.8% [72.6%; 87.0%] 
Percentage of false positives 30.4%  
Percentage of false negatives 4.0%  
 
 
